Based on the preclinical data, methylene blue was rebranded as Rember by TauRx Therapeutics, and moved into a Phase 2 clinical trial involving 321 mild to moderate Alzheimer’s patients, where positive results were seen on a measure of cognition (ADAS-Cog) after 24 weeks on the middle dose (138 mg/day), but no clinical effect was seen at the highest dose, halting further clinical development. [78] A reduced formulation of MB called LMTM (LMT-X, TRx0237) was developed, which showed different pharmacokinetics in animal models and limited human studies involving healthy controls [79].
